The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

Human cysteine proteases of the papain family have been recognized as potential drug targets for musculoskeletal diseases. Most of the interest is focused on cathepsins S and K, which display selective expression in cells of the immune system and cells capable to efficiently degrade extracellular matrix proteins, in particular collagens. The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel anti-resorptive drugs in osteoporosis whereas cathepsin S appears to be an attractive drug target candidate for various inflammatory diseases including rheumatoid arthritis. Since rheumatoid arthritis is at the same time an inflammatory and joint destructive disorder, the combined inhibition of both cathepsins S and K should be beneficial. This review will outline the rationale and recent progress for targeting cathepsins in arthritis and osteoporosis.

[1]  R. Wynn,et al.  Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family* , 1999, The Journal of Biological Chemistry.

[2]  E. Rubenstein,et al.  Scientific American Medicine , 1985 .

[3]  H. Ploegh,et al.  Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages , 2000, The Journal of experimental medicine.

[4]  R. DesJarlais,et al.  Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K. , 1999, Bioorganic & medicinal chemistry letters.

[5]  Yong Wang,et al.  Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. , 2002, Journal of medicinal chemistry.

[6]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[7]  D. Yamashita,et al.  Cathepsin K and the design of inhibitors of cathepsin K. , 2000, Current pharmaceutical design.

[8]  J. Falgueyret,et al.  A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. , 2003, Journal of medicinal chemistry.

[9]  H. Kirschke,et al.  Cathepsin S. The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15). , 1986, The Biochemical journal.

[10]  Y. Fujisawa,et al.  Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. , 1998, Journal of medicinal chemistry.

[11]  S. Carr,et al.  Structure and Design of Potent and Selective Cathepsin K Inhibitors , 1997 .

[12]  R. Bohacek,et al.  Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. , 2001, Journal of medicinal chemistry.

[13]  A. Rudensky,et al.  Lysosomal cysteine proteases regulate antigen presentation , 2003, Nature Reviews Immunology.

[14]  J. Deussing,et al.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. H. Drummond,et al.  Metalloproteinase inhibitors as therapeutics. , 1993, Clinical and experimental rheumatology.

[16]  A. Roessner,et al.  Expression of cathepsin K in the human embryo and fetus , 1999, Developmental dynamics : an official publication of the American Association of Anatomists.

[17]  E. Vuorio,et al.  Accelerated Turnover of Metaphyseal Trabecular Bone in Mice Overexpressing Cathepsin K , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  A. Silman,et al.  Epidemiology and genetics of rheumatoid arthritis , 2002, Arthritis research.

[19]  R. Mitchell,et al.  Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.

[20]  R. DesJarlais,et al.  Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K. , 1998, Journal of medicinal chemistry.

[21]  S. Abramson Et tu, acetaminophen? , 2002, Arthritis and rheumatism.

[22]  E. Shaw Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. , 1994, Methods in enzymology.

[23]  W. Jahnke,et al.  Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. , 2002, Journal of medicinal chemistry.

[24]  D. Heinegård,et al.  Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy. , 1988, The Biochemical journal.

[25]  Bonnie F. Sloane,et al.  Cysteine proteases and tumor progression , 1995 .

[26]  R. Maciewicz,et al.  Cathepsin L‐deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy , 2004, International journal of experimental pathology.

[27]  Lynda J Martin,et al.  Rheumatoid arthritis: symptoms, diagnosis, and management. , 2004, Nursing times.

[28]  J. Delaissé,et al.  Cysteine Proteinases and Matrix Metalloproteinases Play Distinct Roles in the Subosteoclastic Resorption Zone , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  C. Debouck,et al.  Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.

[30]  J. Palmer,et al.  The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant induced arthritis. , 1993, The Journal of rheumatology.

[31]  P. Roughley,et al.  Link protein as a monitor in situ of endogenous proteolysis in adult human articular cartilage. , 1991, The Biochemical journal.

[32]  P. Saftig,et al.  The Bone Lining Cell: Its Role in Cleaning Howship's Lacunae and Initiating Bone Formation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  S. Weiss,et al.  Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Rich,et al.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.

[35]  A. Barrett,et al.  Action of rat liver cathepsin L on collagen and other substrates. , 1982, The Biochemical journal.

[36]  D. N. Deaton,et al.  Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications. , 2004, Journal of Medicinal Chemistry.

[37]  R. Wynn,et al.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.

[38]  J. Pelletier,et al.  Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. , 1997, Arthritis and rheumatism.

[39]  Jeffrey D Peterson,et al.  The design of potent hydrazones and disulfides as cathepsin S inhibitors. , 2003, Bioorganic & medicinal chemistry.

[40]  N. Horiuchi,et al.  Induction of collagenase-2 (matrix metalloproteinase-8) gene expression by interleukin-1beta in human gingival fibroblasts. , 2001, Journal of periodontal research.

[41]  D. Brömme,et al.  Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. , 2002, Chemical reviews.

[42]  Lars Karlsson,et al.  Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Smolen,et al.  DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. , 2003, Clinical and experimental rheumatology.

[44]  M. Mcgrath The lysosomal cysteine proteases. , 1999, Annual review of biophysics and biomolecular structure.

[45]  A. Thiel,et al.  Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. , 2003, Arthritis and rheumatism.

[46]  Vincent Leroy,et al.  Cathepsin S inhibitors , 2004 .

[47]  J. McKerrow,et al.  Cysteine protease inhibitors as chemotherapy for parasitic infections. , 1999, Bioorganic & medicinal chemistry.

[48]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[49]  L. Jacobsson,et al.  Osteoarthritis of the peripheral joints. , 2002, Best practice & research. Clinical rheumatology.

[50]  J. Deussing,et al.  Proteases involved in MHC dass II antigen presentation , 1999, Immunological reviews.

[51]  T. Hardingham,et al.  Proteoglycans: many forms and many functions , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  C. Brinckerhoff,et al.  Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.

[53]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[54]  S. Stevanović,et al.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. , 2003, The Journal of clinical investigation.

[55]  J G Gleason,et al.  Design of potent and selective human cathepsin K inhibitors that span the active site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  B. Bresnihan,et al.  Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[57]  G. Mundy Osteoporosis: pathophysiology and non-pharmacological management. , 2001, Best practice & research. Clinical rheumatology.

[58]  E. Boyce,et al.  The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic Cancers , 1999, The Annals of pharmacotherapy.

[59]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[60]  H. Ploegh,et al.  Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. , 1996, Immunity.

[61]  A. Barrett,et al.  Cathepsin B1. A lysosomal enzyme that degrades native collagen. , 1974, The Biochemical journal.

[62]  J. Kopeček,et al.  Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. , 2002, Biochemistry.

[63]  W. Parks,et al.  Collagenase-1 and collagen in epidermal repair , 1998, Archives of Dermatological Research.

[64]  J. Ellman,et al.  Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. , 2002, Journal of medicinal chemistry.

[65]  A. Rudensky,et al.  Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.

[66]  T. Schirmeister,et al.  Cysteine Proteases and Their Inhibitors. , 1997, Chemical reviews.

[67]  V. Danis,et al.  The effect of gold sodium thiomalate and auranofin on lipopolysaccharide‐induced interleukin‐1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis , 1990, Clinical and experimental immunology.

[68]  L. Moreland,et al.  Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. , 1999, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[69]  Y. Ru,et al.  Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro * , 2001, The Journal of Biological Chemistry.

[70]  B. Jarvis,et al.  Leflunomide , 1999, Drugs.

[71]  B. Gelb,et al.  Cathepsin K Deficiency in Pycnodysostosis Results in Accumulation of Non-Digested Phagocytosed Collagen in Fibroblasts , 2003, Calcified Tissue International.

[72]  M. Karsdal,et al.  Proteinases in bone resorption: obvious and less obvious roles. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[73]  R. DesJarlais,et al.  Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic. , 1998, Journal of medicinal chemistry.

[74]  I. Reid The roles of calcium and vitamin D in the prevention of osteoporosis. , 1998, Endocrinology and metabolism clinics of North America.

[75]  D. Brömme,et al.  Human Cathepsin O2, a Matrix Protein-degrading Cysteine Protease Expressed in Osteoclasts , 1996, The Journal of Biological Chemistry.

[76]  M. Zawadzka,et al.  Molecular mechanisms of neuroprotective action of immunosuppressants ‐ facts and hypotheses , 2004, Journal of cellular and molecular medicine.

[77]  P. Roughley,et al.  Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. , 1990, The Biochemical journal.

[78]  Y. Ru,et al.  A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. , 2002, Bone.

[79]  N. Ishimaru,et al.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. , 2002, The Journal of clinical investigation.

[80]  C. Bayly,et al.  Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[81]  J. Mort,et al.  Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. , 1998, The Biochemical journal.

[82]  R. Gordon,et al.  Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.

[83]  S. Santavirta,et al.  Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. , 2002, Arthritis and rheumatism.

[84]  D. Turk,et al.  Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo. , 2000, Biochemical and biophysical research communications.

[85]  K. Korach,et al.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.

[86]  B. Gelb,et al.  Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.

[87]  A. Hollander,et al.  Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. , 1997, Arthritis and rheumatism.

[88]  R. Fox,et al.  Mechanism of action of hydroxychloroquine as an antirheumatic drug. , 1993, Seminars in arthritis and rheumatism.

[89]  Mary Pat Beavers,et al.  Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.

[90]  E. Eriksen,et al.  European and North American Experience with HRT for the prevention of osteoporosis. , 1996, Bone.

[91]  Teruo Tanaka,et al.  Cathepsins in the osteoclast. , 2003, Journal of electron microscopy.

[92]  M. Kumegawa,et al.  Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. , 1994, The Journal of biological chemistry.

[93]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  A. Hollander,et al.  Molecular Interaction and Matrix Assembly , 1998, The Biochemical journal.

[95]  B. Caterson,et al.  Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. , 1998, Osteoarthritis and cartilage.

[96]  J. Vane,et al.  The mechanism of action of aspirin. , 2003, Thrombosis research.

[97]  G. Obeid,et al.  Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. , 2005, Journal.

[98]  M. Bogyo,et al.  Regulation of Collagenase Activities of Human Cathepsins by Glycosaminoglycans* , 2004, Journal of Biological Chemistry.

[99]  T. Welte,et al.  Expression of cathepsin K in lung epithelial cells. , 1999, American journal of respiratory cell and molecular biology.

[100]  L. Shewchuk,et al.  Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. , 2004, Journal of medicinal chemistry.

[101]  E. Purisima,et al.  3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[102]  S. Goldring,et al.  Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. , 2002, Arthritis and rheumatism.

[103]  Ranjeny Thomas,et al.  Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis? , 1999, Immunology and cell biology.

[104]  D. Brömme,et al.  Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. , 2000, Biochemistry.

[105]  Y. Ru,et al.  Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[106]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[107]  H. Tsuge,et al.  Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells. , 2002, Archives of biochemistry and biophysics.

[108]  P. Emery,et al.  Role of biologics in early arthritis. , 2003, Clinical and experimental rheumatology.

[109]  P. Cresswell Invariant Chain Structure and MHC Class II Function , 1996, Cell.

[110]  Dayer Jm,et al.  Leflunomide: mode of action in the treatment of rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[111]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[112]  A. Hall,et al.  Control of matrix synthesis in isolated bovine chondrocytes by extracellular and intracellular pH , 1995, Journal of cellular physiology.

[113]  D. Veber,et al.  Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors. , 2004, The journal of peptide research : official journal of the American Peptide Society.

[114]  D. Brömme,et al.  Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. , 2002, Current pharmaceutical design.

[115]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[116]  K. Hirohata,et al.  Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro. , 1988, Arthritis and rheumatism.

[117]  G. FitzGerald Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[118]  D. Brömme,et al.  Cleavage Site Specificity of Cathepsin K toward Cartilage Proteoglycans and Protease Complex Formation , 2003, Biological chemistry.

[119]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[120]  L. Polgár,et al.  Current problems in mechanistic studies of serine and cysteine proteinases. , 1982, The Biochemical journal.

[121]  V. Everts,et al.  Effects of the proteinase inhibitors leupeptin and E-64 on osteoclastic bone resorption , 1988, Calcified Tissue International.

[122]  R. Bräuer,et al.  Matrix metalloproteinases, IL-6, and nitric oxide in rat antigen-induced arthritis. , 1998, Clinical and experimental rheumatology.

[123]  J. Palmer,et al.  Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. , 1994, Arthritis and rheumatism.

[124]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[125]  C. Peters,et al.  Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. , 1993, The Journal of biological chemistry.

[126]  Stanley B. Cohen,et al.  An update on bisphosphonates , 2004, Current rheumatology reports.

[127]  F. Tavares,et al.  Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K. , 2004, Journal of medicinal chemistry.

[128]  C. Rorabeck,et al.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.

[129]  B. Cronstein,et al.  The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. , 1996, Journal of immunology.

[130]  G. Guyatt,et al.  VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis , 2002 .

[131]  B. Cronstein,et al.  Molecular action of methotrexate in inflammatory diseases , 2002, Arthritis research.

[132]  J. Pelletier,et al.  The role of cytokines in osteoarthritis pathophysiology. , 2002, Biorheology.

[133]  D. Turk,et al.  Lysosomal cysteine proteases: facts and opportunities , 2001, The EMBO journal.

[134]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[135]  C. Brinckerhoff Joint destruction in arthritis: metalloproteinases in the spotlight. , 1991, Arthritis and rheumatism.

[136]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[137]  L. Lohmander,et al.  Aggrecan degradation in osteoarthritis and rheumatoid arthritis. , 1995, Acta orthopaedica Scandinavica. Supplementum.

[138]  M. Chopp,et al.  A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia , 2001, Brain Research.

[139]  P. Delmas,et al.  The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.

[140]  Y. Ru,et al.  Cyclic ketone inhibitors of the cysteine protease cathepsin K. , 2001, Journal of medicinal chemistry.

[141]  J. Kopeček,et al.  Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. , 2004, International journal of pharmaceutics.

[142]  D. Felson,et al.  Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.

[143]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[144]  Y. Ru,et al.  Azepanone-based inhibitors of human and rat cathepsin K. , 2001, Journal of medicinal chemistry.

[145]  E. Purisima,et al.  6-Acylamino-penam derivatives: synthesis and inhibition of cathepsins B, L, K, and S. , 2002, Bioorganic & medicinal chemistry letters.

[146]  V. Everts,et al.  Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis , 2007, Calcified Tissue International.

[147]  J. Falgueyret,et al.  Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. , 2001, Journal of medicinal chemistry.

[148]  D. Brömme,et al.  Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. , 1995, Biological chemistry Hoppe-Seyler.

[149]  J. Weidner,et al.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. , 1997, The Journal of clinical investigation.

[150]  R A Smith,et al.  Discovery and parallel synthesis of a new class of cathepsin K inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[151]  H. Ploegh,et al.  Proteolysis in MHC class II antigen presentation: who's in charge? , 2000, Immunity.

[152]  D. Turk,et al.  Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo , 1999, FEBS letters.

[153]  J. Palmer,et al.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.